Joseph Frattaroli
2023
In 2023, Joseph Frattaroli earned a total compensation of $580K as Former Chief Financial Officer at Inhibikase Therapeutics, a 1% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $123,000 |
|---|---|
| Option Awards | $48,631 |
| Salary | $408,333 |
| Total | $579,964 |
Frattaroli received $408.3K in salary, accounting for 70% of the total pay in 2023.
Frattaroli also received $123K in non-equity incentive plan and $48.6K in option awards.
Rankings
In 2023, Joseph Frattaroli's compensation ranked 1,816th out of 2,891 executives tracked by ExecPay. In other words, Frattaroli earned more than 37.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,816 out of 2,891 | 37th |
Division Manufacturing | 1,044 out of 1,584 | 34th |
Major group Chemicals And Allied Products | 654 out of 893 | 27th |
Industry group Drugs | 637 out of 856 | 26th |
Industry Biological Products, Except Diagnostic Substances | 169 out of 211 | 20th |
Source: SEC filing on November 18, 2024.
Frattaroli's colleagues
We found one more compensation record of an executive who worked with Joseph Frattaroli at Inhibikase Therapeutics in 2023.
2023
Milton Werner
Inhibikase Therapeutics